Inventor · disambiguated record
Tao Chen
Also filed as: CHEN TAO · CHEN Tao-Tien
39 granted patents·29 pending applications·217 citations·filing 2008–2025
96Inventor score
Files withARDELYX INC22XIAN LIBANG PHARMACEUTICAL CO LTD5MASSACHUSETTS GEN HOSPITAL4XIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD4QYUNS THERAPEUTICS CO LTD3
Top patents by PatentIndex Score
68 records- 0195US9791456B2Method for measuring ATR inhibition mediated increases in DNA damageVERTEX PHARMA·Filed 2015·Granted Oct 17, 2017·17 cites·17 claims
- 0295US9365655B2Soluble heavy-chain only antibodiesKINGDON CRAIG R·Filed 2013·Granted Jun 14, 2016·66 cites·8 claims
- 0395US8999632B2Method for measuring ATR inhibition mediated increases in DNA damageVERTEX PHARMA·Filed 2013·Granted Apr 7, 2015·40 cites·5 claims
- 0494US8883150B2Soluble “heavy-chain only” antibodiesKINGDON CRAIG R·Filed 2010·Granted Nov 11, 2014·53 cites·31 claims
- 0586US10968246B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2019·Granted Apr 6, 2021·2 cites·27 claims
- 0686US8916569B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Dec 23, 2014·7 cites·44 claims
- 0786US8809339B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 19, 2014·8 cites·36 claims
- 0885US8815910B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·38 claims
- 0985US8815908B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·32 claims
- 1083US10385024B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2018·Granted Aug 20, 2019·3 cites·36 claims
- 1180US10392413B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2016·Granted Aug 27, 2019·3 cites·39 claims
- 1279US12312325B2Methods and compounds useful in the synthesis of an AAK1 inhibitorLEXICON PHARMACEUTICALS INC·Filed 2023·Granted May 27, 2025·0 cites·16 claims
- 1379US2025067907A1Compounds and methods for treating hyperkalemiaARDELYX INC·Filed 2024·Application pending·0 cites
- 1475US2023273354A1Glycyrrhetinic acid derivatives for treating hyperkalemiaARDELYX INC·Filed 2023·Application pending·0 cites
- 1572US10329243B2Biphenyl derivative and uses thereofXIAN LIBANG PHARMACEUTICAL CO LTD·Filed 2016·Granted Jun 25, 2019·3 cites·12 claims
- 1672US2024209019A1Compounds and methods for treating hyperkalemiaARDELYX INC·Filed 2023·Application pending·0 cites
- 1772US2025282747A1Methods and compounds useful in the synthesis of an aak1 inhibitorLEXICON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1869US2025388615A9Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonistsARDELYX INC·Filed 2024·Application pending·0 cites
- 1966US9849094B2Eluting matrix and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2016·Granted Dec 26, 2017·0 cites·16 claims
- 2062US9301951B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Apr 5, 2016·0 cites·40 claims
- 2161US12378309B2Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat diseaseQYUNS THERAPEUTICS CO LTD·Filed 2024·Granted Aug 5, 2025·0 cites·6 claims
- 2261US12351626B2Anti-human interleukin-33 monoclonal antibody and use thereofQYUNS THERAPEUTICS CO LTD·Filed 2024·Granted Jul 8, 2025·0 cites·7 claims
- 2360US10580262B2Eluting matrix and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2017·Granted Mar 3, 2020·0 cites·34 claims
- 2459US11858959B2Glycyrrhetinic acid derivatives for use in treating hyperkalemiaARDELYX INC·Filed 2020·Granted Jan 2, 2024·0 cites·22 claims
- 2559US11768319B2Glycyrrhetinic acid derivatives for treating hyperkalemiaARDELYX INC·Filed 2018·Granted Sep 26, 2023·0 cites·18 claims
- 2659US9849159B2Eluting matrix and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2017·Granted Dec 26, 2017·0 cites·23 claims
- 2759US2025235496A1Use of bellidifolin (bel) and/or bel-containing extract in preparation of antidepressant productNORTHWEST INST OF PLATEAU BIOLOGY CAS·Filed 2024·Application pending·0 cites
- 2858US9289429B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 22, 2016·0 cites·33 claims
- 2958US9289430B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 22, 2016·0 cites·35 claims
- 3058US9278102B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 8, 2016·0 cites·29 claims
- 3157US12121498B2Allosteric enhancing compound of GABAA receptor and preparation and use thereofXIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD·Filed 2019·Granted Oct 22, 2024·0 cites·2 claims
- 3257US11684591B2Use of a GABAA receptor allosteric enhancer in medicineXIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD·Filed 2019·Granted Jun 27, 2023·0 cites·3 claims
- 3357US9693963B22,2′,6,6′-tetraisopropyl-4,4′-2-biphenol soft capsule and method for preparing sameWANG RUTAO·Filed 2012·Granted Jul 4, 2017·1 cites·7 claims
- 3456US12084472B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2021·Granted Sep 10, 2024·0 cites·54 claims
- 3556US9775816B2Eluting matrix and uses thereofMASSACHUSETTS GEN HOSPITAL·Filed 2016·Granted Oct 3, 2017·0 cites·23 claims
- 3656US2023313399A1Apparatuses, systems, and methods for generating nitric oxideNANJING NOVLEAD BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 3753US2024254244A1ANTI-HUMAN INTERFERON a RECEPTOR 1 MONOCLONAL ANTIBODY AND APPLICATION THEREOFQYUNS THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 3853US2025127913A1Bifunctional folate receptor binding compoundsLYCIA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3953US2025257401A1Biomarker for tuberous sclerosis complex with no mutation identified in tsc1 or tsc2 gene, and uses thereofGUANGZHOU KINGMED TRANSF MEDICINE INSTITUTE CO LTD·Filed 2022·Application pending·0 cites
- 4053US2024081302A1Method of preparing antibody carrying a universal site-directed coupling interface based on genetically modified vertebrateUNOGEN BIOTECHNOLOGY CO LTD·Filed 2023·Application pending·0 cites
- 4152US2014315755A1Genome-wide Antisense Oligonucleotide and RNAiCHEN TAO·Filed 2013·Application pending·0 cites
- 4251US2015299131A1Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2013·Application pending·0 cites
- 4351US2021244799A1Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing lossUNIV OKLAHOMA·Filed 2021·Application pending·0 cites
- 4450US11576385B2Method for increasing wheat yield and preventing wheat diseases and use thereofUNIV HUAZHONG AGRICULTURAL·Filed 2020·Granted Feb 14, 2023·0 cites·11 claims
- 4549US10154967B22,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparations and preparation methods thereforXIAN LIBANG PHARMACEUTICAL CO LTD·Filed 2016·Granted Dec 18, 2018·0 cites·8 claims
- 4649US2017037010A1Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2016·Application pending·0 cites
- 4748US2019264200A1Generic System of Antisense OligonucleotideCHEN TAO·Filed 2017·Application pending·0 cites
- 4846US8263039B2Use of DKK-1 protein in the cancer diagnosisQIN WENXIN·Filed 2008·Granted Sep 11, 2012·0 cites·6 claims
- 4945US2022016187A1Lactobacillus paracasei and its application in preparation of medicine for treating ulcerative colitisFOSHAN LANGSEE BIOTECHNOLOGY CO LTD·Filed 2020·Application pending·0 cites
- 5045US2022023219A1Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereofXIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 68 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tao Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →